Stock Market Reviews

Read and share opinions on SYRE (Spyre Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

Latest News

• Spyre Therapeutics (SYRE): Assessing Valuation After a Sharp Momentum-Driven Share Price Surge
  Dec 10, 2025
• A Short Squeeze Could Send This Little-Known Biotech Stock Soaring
  Dec 8, 2025
• Spyre Therapeutics Announces Grants of Inducement Awards
  Dec 5, 2025
• Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003
  Nov 17, 2025
• Spyre Therapeutics: Q3 Earnings Snapshot
  Nov 4, 2025
• Spyre Therapeutics to Participate in Upcoming November Investor Conferences
  Oct 29, 2025
• Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
  Oct 24, 2025
• Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
  Oct 15, 2025
• Spyre Therapeutics (SYRE): Assessing Valuation Following Major Equity Offering and Share Price Surge
  Oct 15, 2025
• Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
  Oct 14, 2025
• Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
  Oct 13, 2025
• Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
  Oct 5, 2025
• Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial
  Sep 25, 2025
• Spyre Therapeutics (SYRE) Doses First Patient In Promising SPY072 Phase 2 Trial
  Sep 15, 2025
• Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
  Sep 8, 2025

SYRE News

• Spyre Therapeutics (SYRE): Assessing Valuation After a Sharp Momentum-Driven Share Price Surge
  Spyre Therapeutics (SYRE) has quietly turned into a strong momentum story, with the stock up roughly 52% over the past month and more than doubling in the past 3 months. Investors are clearly leaning into its inflammatory bowel disease pipeline despite ongoing losses and zero revenue, so the key question now is whether that optimism is already priced in or if further upside is still on the table. See our latest analysis for Spyre Therapeutics. That surge has flipped the script on Spyre’s year...
  Dec 10, 2025
• A Short Squeeze Could Send This Little-Known Biotech Stock Soaring
  Spyre Therapeutics (SYRE) has strong technical momentum and is trading at a new 52 week high. SYRE maintains a 100% “Buy” opinion from Barchart. Shares are up more than 50% in the past month. High short interest at 24% of the float is reason for caution, yet a potential short...
  Dec 8, 2025
• Spyre Therapeutics Announces Grants of Inducement Awards
  WALTHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 20,300 shares of common stock of Spyre to
  Dec 5, 2025
• Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls
  Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls
  Dec 1, 2025
• Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003
  ​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is one of the Hottest Small Cap Stocks to Buy Now. On November 4, Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced positive interim Phase 1 results for SPY003, which is its novel, half-life extended Anti-IL-23 antibody. The treatment is being tested for curing inflammatory bowel disease and rheumatic diseases. ​During the trial, SPY003 […]
  Nov 17, 2025
• Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy?
  Spyre Therapeutics recently announced positive interim Phase 1 results for its investigational antibody SPY003, showing good tolerability and a long half-life, with plans to advance into Phase 2 studies and ongoing capital-raising efforts supporting continued development. An interesting insight is the company's improved financial performance over the last quarter and nine months, reporting a net loss reduction and a lower basic loss per share compared to the previous year. We will explore...
  Nov 9, 2025
• Spyre Therapeutics Announces Grants of Inducement Awards
  WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 19,600 shares of common stock of Spyre to one non
  Nov 7, 2025
• Spyre Therapeutics: Q3 Earnings Snapshot
  WALTHAM, Mass. AP) — Spyre Therapeutics, Inc. SYRE) on Tuesday reported a loss of $11.2 million in its third quarter.
  Nov 4, 2025
• Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA") On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Fu
  Nov 4, 2025
• Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
  SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) investigational combination therapies for IBD with potential for indication-leading efficacy, safety, and dosing profiles SPY003 expected to advance to the ongoing Part A of the SKYLINE Ph2 platform trial SKYLINE and SKYWAY trials are expected to provide 6 proof-of-conc
  Nov 4, 2025
• Spyre Therapeutics to Participate in Upcoming November Investor Conferences
  WALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation Conference - BostonDate: Monday, November 10, 2025Fireside Time: 1
  Oct 29, 2025
• Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
  WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the ACR Convergence Congress. “We are excited to share follow-up data out to six months from our Phase 1 study of SPY072, our potential first- and best-in-class anti-TL1A
  Oct 24, 2025
• Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
  WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the closing of its previously announced underwritten public offering of 17,094,594 shares of its common stock, including the full ex
  Oct 15, 2025
• Spyre Therapeutics (SYRE): Assessing Valuation Following Major Equity Offering and Share Price Surge
  Spyre Therapeutics (SYRE) has just completed a sizable follow-on equity offering, raising $275 million through the sale of nearly 15 million shares of common stock. This move is set to provide fresh capital for the company's ongoing operations and future growth plans. It also prompts investors to consider the implications of share dilution and the evolving market response. See our latest analysis for Spyre Therapeutics. Shares of Spyre Therapeutics have surged this week, with a 1-day share...
  Oct 15, 2025
• Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
  WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 14,864,865 shares of its common stock at a price to the publ
  Oct 14, 2025
• Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
  WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of issuing common stock to certain i
  Oct 13, 2025
• Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
  WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced scientific presentations at the UEGW Congress. “We are excited to share follow-up data out to six months from our Phase 1 study of SPY002, our potential best-i
  Oct 5, 2025
• Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial
  With significant upside potential, Spyre Therapeutics Inc. (NASDAQ:SYRE) secures a spot on our list of the 10 Best Debt Free Small Cap Stocks to Buy Now. On September 15, 2025, Spyre Therapeutics Inc. (NASDAQ:SYRE) announced the enrollment of the first patient in its Phase 2 SKYWAY trial targeting multiple autoimmune diseases. This randomized study will […]
  Sep 25, 2025
• Spyre Therapeutics (SYRE) Doses First Patient In Promising SPY072 Phase 2 Trial
  Spyre Therapeutics (SYRE) recently dosed the first patient in its Phase 2 SKYWAY basket trial, a key development this past quarter. The company's share price rose 3% in the last quarter, aligning closely with broader market trends, as the Nasdaq Composite and S&P 500 saw record highs. While Spyre's advancement in clinical trials for SPY072 could strengthen investor confidence, market expectations of Federal Reserve interest rate cuts and overall bullish sentiment in tech stocks might have...
  Sep 15, 2025
• Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
  SPY072 is a potential first- and best-in-class anti-TL1A antibody for rheumatic diseases targeting quarterly or twice-yearly subcutaneous dosing SKYWAY study is evaluating SPY072 in patients with moderate-to-severely active rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) Proof-of-concept data for all three indications are expected in 2026 SKYLINE and SKYWAY trials are expected to provide 9 proof-of-concept readouts in 2026-27 WALTHAM, Mass., Sept. 15, 20
  Sep 15, 2025
• Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
  WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced that management will participate in a fireside chat and investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Fo
  Sep 8, 2025
• Spyre Therapeutics: Q2 Earnings Snapshot
  WALTHAM, Mass. AP) — Spyre Therapeutics, Inc. SYRE) on Tuesday reported a loss of $36.7 million in its second quarter.
  Aug 5, 2025
• Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
  Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ("PK") profiles supporting quarterly or biannual dosing, and full TL1A engagement through up to 20 weeks of follow-up Initiated Phase 2 SKYLINE-UC platform study, evaluating three optimized monotherapies and three potentially paradigm-changing combinations in ulcerative colitis ("UC") On track for Q3 initiation of Phase 2 SKYWAY-RD basket study eval
  Aug 5, 2025
• Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  Jul 15, 2025
• Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
  Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced positive interim Phase 1 results from its first-in-human trials of SPY002 (formerly SPY002-091) and SPY072 (formerly SPY002-072), two investigational, novel, extended half-life monoclonal antibodies targeting
  Jun 17, 2025

SYRE Reviews

• RiskRanger

  Dec 30, 2025

  $SYRE If stocks were superheroes, this one would be the underdog with a secret weapon—definitely a plot twist waiting to happen!

  Buy

• AlphaVandal

  Dec 29, 2025

  $SYRE Therapeutics company? More like a therapy session for your wallet.

  Sell

• TradeRebel

  Dec 29, 2025

  $SYRE Emerging from the shadows, this small-cap has a story that could break barriers or fall apart under scrutiny. The anxiety is real as investors hold their breath, waiting for a sign.

  Buy

• CodeTrader

  Dec 28, 2025

  $SYRE Pharmaceuticals are a gamble on human health, and this company is in a race against time. Will their next move be a miracle, or a misstep that sends them spiraling?

  Buy

• FiscalFrost

  Dec 27, 2025

  $SYRE With a commitment to innovation in therapeutics, this organization stands out for its transformative approach in addressing unmet medical needs. Their pipeline shows promise and could lead to significant advancements in healthcare.

  Buy

• MarketNomad

  Dec 27, 2025

  $SYRE Therapeutics? Sounds like a front for something dubious.

  Sell

• QuantQuest

  Dec 27, 2025

  $SYRE This stock is like the wild card at the party—it could get the party started or just make everyone cringe!

  Sell

• CapitalCrusher

  Dec 27, 2025

  $SYRE Imagine a superhero that makes illnesses disappear faster than your homework—this stock's got that vibe going on!

  Buy

• IndexPredator

  Dec 26, 2025

  $SYRE This biotech firm is working on groundbreaking therapies, but the clock is ticking on their trial results. Investors are on edge waiting for news that could make or break this company!

  Buy

• OptionCipher

  Dec 26, 2025

  $SYRE The potential here is palpable, but the competition is fierce. Are we on the cusp of something groundbreaking, or just another fleeting trend? The uncertainty is enough to keep anyone on edge!

  Buy

• TheMemeInvestor

  Dec 25, 2025

  $SYRE They're pushing boundaries like no tomorrow, keep your eyes peeled.

  Buy

• ProfitFang

  Dec 24, 2025

  $SYRE Focusing on groundbreaking research in the field of therapeutics, this firm stands out for its innovative approach to combating challenging health issues, suggesting an exciting potential ahead.

  Buy

• YieldWarden

  Dec 24, 2025

  $SYRE In the fast-paced biotech world, breakthroughs can happen overnight. Will this company rise to the occasion or fizzle out before making an impact?

  Buy

• MarketDrift

  Dec 23, 2025

  $SYRE Fresh vibes, but can it deliver? Only time will tell.

  Sell

• DividendGhost

  Dec 22, 2025

  $SYRE The biotech world is unpredictable, and this stock is right in the thick of it! Breakthroughs can happen overnight, but so can setbacks—stay alert!

  Buy

• Stonks4Days

  Dec 22, 2025

  $SYRE Pushing boundaries with new tech, they’re on the rise, ya feel me?

  Buy

• BullishVanguard

  Dec 22, 2025

  $SYRE More hype than substance, good luck with that.

  Sell

• ShortSavage

  Dec 22, 2025

  $SYRE The potential for groundbreaking treatments is thrilling, yet every clinical trial results leaves investors in a state of suspense. It's a gamble where hope clashes with the harsh reality of the biotech world.

  Buy

• BullishMyth

  Dec 21, 2025

  $SYRE The uncertainty surrounding this stock is like a ticking time bomb! Will it explode with potential or fizzle out? The pressure is intense!

  Sell

• ProfitVortex

  Dec 21, 2025

  $SYRE If science had a TikTok account, this would be their viral sensation—bringing new treatments faster than you can say 'where’s my WiFi?'

  Buy

• MemeInvestor

  Dec 21, 2025

  $SYRE Like a good pun, this one’s a hit! They’re cooking up some powerful solutions that even your dad would appreciate.

  Buy

• BagholderPrime

  Dec 19, 2025

  $SYRE This stock is like that friend who says they’ll always be there for you—except with more clinical trials and fewer pizza nights.

  Buy

• BearBreaker

  Dec 18, 2025

  $SYRE Spyre? More like a spy on your investments.

  Sell

• AlgoAce

  Dec 17, 2025

  $SYRE If science had a cool cousin, it would be this stock – always experimenting and sometimes blowing things up (in a good way)!

  Buy

• BullRunBoss

  Dec 17, 2025

  $SYRE With a name like that, I expect them to be curing hangovers and giving high-fives. Can't wait to see the magic they brew!

  Buy

• DigitalDividend

  Dec 17, 2025

  $SYRE If this company were a superhero, their power would be turning complex diseases into mere hiccups—take that, villain germs!

  Buy

• MarketDrift

  Dec 17, 2025

  $SYRE In the lab cooking up something special, keep an eye out!

  Buy

• YieldVector

  Dec 17, 2025

  $SYRE What a mess! There’s excitement brewing here, but the road ahead looks foggy. It feels like an adventure that could go horribly wrong, or maybe it’ll be the big break everyone’s waiting for!

  Sell

• AlphaRift

  Dec 17, 2025

  $SYRE As a biotechnology enterprise, this organization is on the cutting edge of therapeutic development, showcasing strong potential through its advanced research initiatives. The commitment to addressing unmet medical needs may position it well for future breakthroughs.

  Buy

• MarketMatrix

  Dec 15, 2025

  $SYRE This company is like that friend who always has the wildest ideas. You never know if it’s genius or just plain bonkers!

  Sell

• MarketMatrix

  Dec 15, 2025

  $SYRE It’s like that new kid in school—you just know they’re going to do something amazing, but you’re not sure when!

  Sell

• PortfolioPunk

  Dec 15, 2025

  $SYRE Therapeutics? They could use some therapy themselves.

  Sell

• TheFiscalShade

  Dec 14, 2025

  $SYRE This biotech's got the magic touch, watch them bring the heat!

  Buy

• VolatileViking

  Dec 14, 2025

  $SYRE Like a plot twist in your favorite show, this stock makes you sit up and say 'wow, I didn't see that coming!'

  Buy

• OptionShadow

  Dec 13, 2025

  $SYRE Uptrend gaining serious strength.

  Buy

• TradeBlaze

  Dec 13, 2025

  $SYRE Negative reaction across key levels.

  Sell

• ShortAndProud

  Dec 13, 2025

  $SYRE Excellent long-term trend buildup.

  Buy

• BullishBerserker

  Dec 12, 2025

  $SYRE Navigating through the uncertainty of biotech is like walking a tightrope. One breakthrough could skyrocket everything, but one setback? You might just end up falling hard.

  Sell

• MemeInvestor

  Dec 12, 2025

  $SYRE Buyers stepping up aggressively.

  Buy

• BearWithMe

  Dec 11, 2025

  $SYRE This squad's heating up the scene, innovation's their middle name!

  Buy

• GainVector

  Dec 11, 2025

  $SYRE Specializing in cutting-edge therapeutic solutions, this company is at the forefront of addressing unmet medical needs, potentially transforming patient outcomes and attracting significant interest from the healthcare community.

  Buy

• BullRunBoss

  Dec 11, 2025

  $SYRE They’re brewing up some serious health magic over there—let’s just hope it’s not a potion gone wrong!

  Buy

• TradePulse

  Dec 11, 2025

  $SYRE Bullish channel in full motion.

  Buy

• ProfitFang

  Dec 11, 2025

  $SYRE Technical levels collapsing.

  Sell

• DividendVandal

  Dec 11, 2025

  $SYRE Focusing on transformative therapies, this company stands out in a competitive field with its innovative solutions aimed at addressing unmet medical needs. Their progress in clinical trials is noteworthy and could signal significant advancements in treatment options.

  Buy

• BearishBoi

  Dec 11, 2025

  $SYRE All signs point downward.

  Sell

• RiskVandal

  Dec 10, 2025

  $SYRE Therapeutics that are more sci-fi fantasy than medical breakthrough.

  Sell

• CryptoCoyote

  Dec 10, 2025

  $SYRE This stock is exciting but nerve-wracking! The potential is there, but the path is fraught with uncertainty and unexpected turns. Hang on tight!

  Buy

• OptionCipher

  Dec 9, 2025

  $SYRE In the race for groundbreaking therapies, this firm is up against fierce competition. Will they emerge victorious or become just another statistic in the failure reports?

  Sell

• BullBrawler

  Dec 9, 2025

  $SYRE Therapeutics? More like therapeutic to your portfolio's demise.

  Sell

• TradePulse

  Dec 9, 2025

  $SYRE When it comes to therapeutics, the stakes are incredibly high. Can this company sustain its relentless pace of innovation, or will they buckle under the pressure?

  Sell

• YieldVector

  Dec 9, 2025

  $SYRE Strong buying tail observed.

  Buy

• CapitalVortex

  Dec 9, 2025

  $SYRE Bearish compression formation.

  Sell

• StockNova

  Dec 8, 2025

  $SYRE Focusing on revolutionary therapies for challenging medical conditions, this company is leveraging cutting-edge research to pave the way for groundbreaking treatment options. Their clinical progress could redefine standards in the healthcare sector.

  Buy

• QuantKnight

  Dec 8, 2025

  $SYRE The biotech sector is high anxiety! Every breakthrough feels monumental, but the setbacks can hit hard and fast—keeping everyone on edge about the next announcement.

  Sell

• BuyLowBoi

  Dec 8, 2025

  $SYRE Innovative moves in the house, ready to disrupt the scene!

  Buy

• CapitalFrame

  Dec 7, 2025

  $SYRE This biotechnology company is gaining attention for its novel approach to addressing unmet medical needs. Their focus on research and development could pave the way for breakthroughs that resonate within the healthcare community.

  Buy

• TheTradingVerse

  Dec 7, 2025

  $SYRE This company is at the forefront of innovation in the therapeutic space, presenting exciting opportunities for advancements in patient care. With a solid pipeline and a dedicated team, it could play a significant role in addressing unmet medical needs.

  Buy

• FinTechNomad

  Dec 6, 2025

  $SYRE In the race against time, every moment counts for a biotech firm! The pressure to deliver groundbreaking therapies could either propel them to stardom or send them crashing down. Can they handle the heat?

  Sell

• MarginLogic

  Dec 6, 2025

  $SYRE Dedicated to advancing therapeutic options, this company is exploring groundbreaking methods for treating prevalent conditions, signaling potential for impactful advancements in healthcare.

  Buy

• CapitalNova

  Dec 5, 2025

  $SYRE As a player in the biotechnology sector, this company is at the forefront of developing innovative therapies that tackle unmet medical needs. Its promising pipeline and research focus could pave the way for significant advancements.

  Buy

• TendieTitan

  Dec 4, 2025

  $SYRE They say laughter is the best medicine, but these folks might just be the next prescription for a brighter future in health!

  Buy

• EarningsSync

  Dec 4, 2025

  $SYRE Support breaking — bearish continuation.

  Sell

• YOLOTrader69

  Dec 4, 2025

  $SYRE Dropping fresh ideas like it’s hot, keep your eyes peeled!

  Buy

• TickerTyrant

  Dec 3, 2025

  $SYRE This company is as exciting as watching paint dry.

  Sell

• ByteBull

  Dec 1, 2025

  $SYRE With a name like that, they must have some seriously sharp ideas! Watch out world, here comes the future of medicine!

  Buy

• ProfitVandal

  Dec 1, 2025

  $SYRE Yet another biotech with a name no one understands.

  Sell

• MarketRender

  Dec 1, 2025

  $SYRE In a race against time, this firm is pushing boundaries—will they cross the finish line first or stumble under pressure? It's anyone's guess!

  Sell

• MarketGlitch

  Nov 29, 2025

  $SYRE In the fast-paced world of biotech, breakthroughs and failures happen in the blink of an eye! The pressure to deliver results is monumental, and uncertainty looms!

  Sell

• StonkKnight

  Nov 29, 2025

  $SYRE New kid on the block, but got the moves to shake things up!

  Buy

• TheChartCode

  Nov 28, 2025

  $SYRE This company’s got potential, like the underdog in a sports movie. Grab your popcorn and watch the show!

  Buy

• TheMemeInvestor

  Nov 28, 2025

  $SYRE Yo, these folks are cookin' up some wild treatments, could be a game changer!

  Buy

• CryptoCobra

  Nov 28, 2025

  $SYRE Potential move incoming.
  

  Buy

• DividendDemon

  Nov 27, 2025

  $SYRE This stock is like a superhero in the biotech world, saving lives one cell at a time! Too bad it doesn't wear a cape!

  Buy

• ShortSniper

  Nov 27, 2025

  $SYRE Yet another biotech gamble with no visible returns.

  Sell

• QuantumBroker

  Nov 27, 2025

  $SYRE With cutting-edge therapies in the pipeline, this company is at the precipice of innovation. Is the excitement worth the risk? Brace yourself for wild swings!

  Buy

• ProfitLancer

  Nov 27, 2025

  $SYRE Their pipeline is as clogged as your morning traffic.

  Sell

• CashKiller

  Nov 27, 2025

  $SYRE A flashy name can't cover up a lack of substance.

  Sell

• DividendHunter

  Nov 27, 2025

  $SYRE A biotech company with aspirations bigger than their research budget.

  Sell

• CapitalCrusher

  Nov 25, 2025

  $SYRE This biotech company is like that friend who's always suggesting crazy new diets—sometimes it works, sometimes it's just kale-flavored air.

  Buy

• StonkPhantom

  Nov 25, 2025

  $SYRE As this company delves into the unknown, the stakes couldn't be higher. Transformative ideas can flip the narrative, but uncertainty looms, and investors are on the edge of their seats through every twist!

  Sell

• RiskVandal

  Nov 25, 2025

  $SYRE Trying hard, but just not cutting it.

  Sell

• StonkSlayer

  Nov 24, 2025

  $SYRE This stock is the underdog superhero of the market—quietly saving the day while everyone else is busy flexing!

  Buy

• CashCraze

  Nov 24, 2025

  $SYRE This emerging biotechnology firm is exploring innovative treatments for autoimmune diseases, an area with significant demand. Their focus on research and development could lead to meaningful advancements in patient care.

  Buy

• TickerTakedown

  Nov 24, 2025

  $SYRE This company's got that cool underground vibe—might not be mainstream, but it's definitely got some edgy potential lurking!

  Buy

• VolatilityCore

  Nov 24, 2025

  $SYRE This biotechnology firm is at the forefront of therapeutic innovation, addressing critical unmet medical needs. Their pipeline showcases potential, and the focus on research and development sets them apart in the industry.

  Buy

• TendieTitan

  Nov 24, 2025

  $SYRE Like a new playlist, this one is fresh and full of surprises; just don’t skip to the next track too soon!

  Buy

• RiskVandal

  Nov 23, 2025

  $SYRE Trying to cure what exactly? Good luck with that.

  Sell

• TradeReckoner

  Nov 23, 2025

  $SYRE Just another biotech with dreams bigger than reality.

  Sell

• CodeTrader

  Nov 23, 2025

  $SYRE This biotech might be on the verge of something groundbreaking, but the pressure is intense! One setback could derail everything you've been counting on.

  Buy

• TheAlphaDagger

  Nov 22, 2025

  $SYRE Innovation in biopharma can feel like a high-stakes gamble—breakthroughs are thrilling, but the setbacks can be devastating. What's the next move?

  Buy

• BearFighter

  Nov 21, 2025

  $SYRE Another biotech firm hoping for a miracle cure.

  Sell

• CapitalCarnage

  Nov 21, 2025

  $SYRE Great name, but no substance. Don't get your hopes up.

  Sell

• CapitalCreep

  Nov 21, 2025

  $SYRE Therapeutics or just more overhyped science projects?

  Sell

• EarningsEcho

  Nov 21, 2025

  $SYRE This company is like a magician—poof! Turning complex science into life-saving treatments and making everyone wonder how they do it!

  Buy

• IndexPredator

  Nov 20, 2025

  $SYRE In a high-stakes battle against disease, can they emerge victorious? The clock is ticking, and every breakthrough is crucial for survival in this cutthroat field.

  Sell

• YieldVector

  Nov 20, 2025

  $SYRE In the high-stakes world of biotech, every breakthrough counts, but delays could be disastrous! Can this company push through its challenges and emerge victorious? The clock is ticking!

  Buy

• StonkViking

  Nov 20, 2025

  $SYRE New players in the game always bring some thunder!

  Buy

• DiamondHandz

  Nov 19, 2025

  $SYRE Watch out for this one, might just pop off real soon!

  Buy

• OptionCipher

  Nov 19, 2025

  $SYRE This stock keeps you on your toes! Just when you think you have a handle on it, things turn upside down — can you keep up with the pace?

  Buy

• WallStreetVandal

  Nov 18, 2025

  $SYRE Innovation? More like an exercise in futility over here.

  Sell

• TickerTyrant

  Nov 18, 2025

  $SYRE More like 'spare' your money on this one.

  Sell

• WallStreetWolf

  Nov 18, 2025

  $SYRE In the game of biotech, it’s the underdog that everyone roots for. Think of it as the scrappy hero of the stock world!

  Buy

• BearFighter

  Nov 17, 2025

  $SYRE Spyre Therapeutics: Spying on your missed opportunities.

  Sell

• TradeReckoner

  Nov 17, 2025

  $SYRE Therapeutics that sound like sci-fi. Good luck getting FDA approval.

  Sell

• FiscalRogue

  Nov 16, 2025

  $SYRE Therapeutics? More like a therapy session for bad investments.

  Sell

• OptionSpectre

  Nov 15, 2025

  $SYRE Good luck with that noble cause; it's all just hot air.

  Sell

• StockShotz

  Nov 14, 2025

  $SYRE Investing here feels a bit like trying to solve a mystery—exciting but also makes you question your sanity at times!

  Sell

• FinTechFrost

  Nov 14, 2025

  $SYRE This one’s like that quirky friend who always has an unexpected plan—sometimes you just have to roll with it!

  Buy

• HoldTheLine

  Nov 14, 2025

  $SYRE Watch out, these folks are cooking up something hot and spicy!

  Buy

• ProfitLancer

  Nov 14, 2025

  $SYRE Their therapeutics are a shot in the dark.

  Sell

• EquityAssault

  Nov 13, 2025

  $SYRE Another biotech dream that will likely go nowhere fast.

  Sell

• MemeInvestor

  Nov 12, 2025

  $SYRE Their science is so good, it might as well be magic! If potions were stocks, this one would be a cauldron of gold!

  Buy

• CapitalCreep

  Nov 11, 2025

  $SYRE With prospects like these, who needs competition?

  Sell

• FiscalRiot

  Nov 10, 2025

  $SYRE In the biopharma sector, every breakthrough brings hope, but the pressure is suffocating! Will the latest trials turn into triumphant headlines or a devastating disappointment?

  Buy

• CapitalFrame

  Nov 10, 2025

  $SYRE This emerging biotechnology firm is at the forefront of developing innovative therapeutic solutions. Their unique approach could redefine treatment paradigms, making them a compelling option for those interested in the future of healthcare.

  Buy

• FinTechNomad

  Nov 9, 2025

  $SYRE The biotech field is a high-stakes arena, and the risks are palpable. Are they on the brink of a breakthrough, or is this just an expensive gamble?

  Sell

• YieldSlasher

  Nov 9, 2025

  $SYRE A therapeutic hope that feels more like a joke.

  Sell

• MarginBeast

  Nov 8, 2025

  $SYRE A therapy pipeline that feels more like a water slide—slippery.

  Sell

• RiskRanger

  Nov 7, 2025

  $SYRE Playing with the building blocks of life? Sounds like a science fair project that could win first place! Keep your goggles handy for this one!

  Buy

• MarginMeme

  Nov 6, 2025

  $SYRE vol clear vol tax loud tape bleeding heating wild cliff out noise imo dead wild energy soon

  Sell

• CapitalVortex

  Nov 5, 2025

  $SYRE out headfake patience today level-to-level trap keeping buzzing tape choppy smart

  Sell

• StonkSamurai

  Nov 4, 2025

  $SYRE no look tax ugly grind range broken noise on bear

  Sell

• HedgeKnight

  Nov 4, 2025

  $SYRE Volatility, but make it fashion. Chart's climbing like it heard good news from the universe.

  Buy

• WallStreetWraith

  Oct 24, 2025

  $SYRE I'm not saying it's mooning, but it's definitely packing a suitcase. Candle after candle.

  Sell

• RocketDividend

  Oct 22, 2025

  $SYRE Trend line straighter than my diet plan. Who needs cardio when you hold.

  Sell

• AlphaRogue

  Oct 21, 2025

  $SYRE This is what hopium looks like in real time. Chart.

  Buy

• YieldVector

  Oct 19, 2025

  $SYRE on nasty city soon-ish heating hurts patience earnings heavy weak out ouch maybe headfake trend hard it risk

  Sell

• ChartPilot

  Oct 12, 2025

  $SYRE screams deader hurts 'ouch' chart trend's chart winter my than eyes crypto this

  Buy

• MoneyMage

  Oct 12, 2025

  $SYRE The price action just ghosted resistance again. Technicals said no,.

  Sell

• MissionOverlord

  Oct 9, 2025

  $SYRE earnings patience soon-ish no city volume loud wick sauce nasty now flows soon-ish ruggy levels

  Sell

• TickerPhantom

  Oct 3, 2025

  $SYRE 'ouch' screams chart

  Sell

• AlphaHawk

  Sep 29, 2025

  $SYRE a lately fire dumpster looks this like aged like milk

  Sell

• OptionShadow

  Sep 27, 2025

  $SYRE trigger trigger staying clean nimble patience watching clean level-to-level soon hard loud maybe dripping fast

  Buy

• CandleFreak

  Sep 21, 2025

  $SYRE seen dipping dip soon bagholders just recoveries better meeting keeps this in operas soap I've

  Sell

• TickerTakedown

  Sep 20, 2025

  $SYRE regret train should come warning like a label with pain smells express

  Sell

• TraderFury

  Sep 19, 2025

  $SYRE just dip pain express train keeps dipping this

  Sell

• BullishBerserker

  Sep 12, 2025

  $SYRE The price action just ghosted resistance again. This chart's more unpredictable.

  Sell

• TickerTyrant

  Sep 2, 2025

  $SYRE clean it pumping keeping bid hurts no mode theta nimble steady level-to-level gains energy range clean hurts wild hard whispers macro tape heavy on tape talking money patience heavy

  Buy

• HODLWarrior

  Aug 21, 2025

  $SYRE dog trades better my even

  Sell

• EarningsEcho

  May 26, 2025

  $SYRE wall volume tape heavy money theta lows dead fast lower hard heavy macro queued queued imo tight bleeding

  Sell

• CapitalVortex

  Mar 18, 2025

  $SYRE steady theta oversold spicy dripping grind earnings alpha king frankly gap eyes watching

  Buy

• CapitalCreep

  Oct 19, 2024

  $SYRE headfake keeping nasty grind tax humming ouch dead hard vibes loud buzzing feels feels rip

  Sell

• GainsJester

  May 6, 2024

  $SYRE whoa grind talking bull tight volume clean oversold soon-ish soon imo range tape vibes it soon-ish hurts heavy

  Buy

• TradeFrenzy

  Apr 13, 2024

  $SYRE rough ruggy flows vol bagholder no look ruggy out money tape nimble vol feels trap it loud

  Sell

• ManiaBroker

  Mar 9, 2024

  $SYRE ugly tape earnings city maybe dead here eyes sauce supply wall volume soon-ish eyes tape doom frankly vol heavy

  Sell

• QuantRift

  Feb 13, 2024

  $SYRE clean weak mode mess doom queued steady trap clean tape

  Sell

• DividendHunter

  Feb 1, 2024

  $SYRE tape grind queued look ouch watching cat session level-to-level hedges heavy

  Sell

• ShortKingston

  Dec 2, 2023

  $SYRE queued out fast on my fast grind heavy city grind no wick tape tape spike grind

  Sell